Zirabev®
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Cervical cancer
DATE:
14/02/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Cervical cancer
DATE:
14/02/2019
STATUS:
Authorized